Sugi Predict

Sugi Predict / Compounds / SCHEMBL18854333

SCHEMBL18854333

SCHEMBL18854333

CC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CS

nearest known ligand 0.57

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ERAP2 Q6P179 3/20 0.57
▸ IL1RN P18510 2/20 0.52
▸ ERAP1 Q9NZ08 2/20 0.52
▸ NPBWR1 P48145 11/20 0.52
▸ GHSR Q92847 1/20 0.51
▸ KISS1R Q969F8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18854324 0.94 ERAP2 (0.58) ERAP2IL1RNERAP1NPBWR1
SCHEMBL31177125 0.90 NPBWR1 (0.59) NPBWR1GHSR
SCHEMBL31177126 0.90 NPBWR1 (0.59) NPBWR1GHSR
SCHEMBL18862075 0.88 NPBWR1 (0.60) ERAP2NPBWR1
SCHEMBL7327449 0.87 ERBB2 (0.61) NPBWR1KISS1R
SCHEMBL31177129 0.86 UTS2R (0.61) NPBWR1GHSR
SCHEMBL31177130 0.86 UTS2R (0.61) NPBWR1GHSR
SCHEMBL38652462 0.85 ERAP2 (0.64) ERAP2IL1RNERAP1GHSRKISS1R
SCHEMBL30465909 0.85 ERAP2 (0.70) ERAP2IL1RNERAP1GHSR
SCHEMBL29691762 0.85 ERAP2 (0.70) ERAP2IL1RNERAP1GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851367-B2 Tissue-specific genome engineering using CRISPR-Cas9 PFIZER INC. (US) 2020-12-01 — — US disclosed
US-20170137801-A1 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-05-18 — — US disclosed
US-20170137801-A1 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851367-B2 Tissue-specific genome engineering using CRISPR-Cas9 ASGR1, LDLR, HAVCR2 ERAP2 411/4885IL1RN 1550/4885ERAP1 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback